In order to step up its performance on innovation, Canada must fix the many inequities in its intellectual property rights regime.
As currently written, the federal government’s Patented Medicines Regulations for biopharmaceutical companies place our life sciences sector at a distinct disadvantage to our international competitors in terms of the hoops innovative companies must jump through to ensure protection of their legitimate intellectual property.
In an official submission to the federal government, the OCC calls on the government to protect the competitiveness of our life sciences industry through the creation of a clear and streamlined Intellectual Property Rights framework.
